Observational analysis shows cilta-cel improves progression-free survival in relapsed/Refractory multiple myeloma, suggesting safety and potential for new biomarkers.
Key Points
This research aims to evaluate the efficacy and safety of cilta-cel following prior BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma.
Identified 9 patients with relapsed/refractory multiple myeloma receiving cilta-cel after BCMA CAR-T therapy.
Assessed outcomes including progression-free survival, overall survival, and toxicity after cilta-cel administration.
Analyzed serum proteome to find potential biomarkers of response at three time points: day 0, day 28, and 6 months.
7 out of 9 patients achieved a response with cilta-cel, showing improved progression-free survival of 31 months.
Cytokine-release syndrome occurred in 4 patients, indicating potential safety issues.
One patient experienced Guillain-Barré syndrome as a delayed neurotoxicity.